Make the implementation case as carefully as the price case.

A biological medicines opportunity can require coordination across specialist teams, pharmacy, procurement, administration services and patient communication. The commercial comparison is incomplete if it assumes that implementation happens without effort. Our proposed PHARMORIS evaluation concerns the organisational preparation for an agreed best-value medicines programme. It would help a team examine what must be in place, which assumptions remain open and how the work could be reviewed. Individual treatment choices and clinical suitability remain with the responsible professionals and people receiving care.

In development · Intended scope and questions for evaluation

The organisation.
The people around it.

A formulary implementation or discharge programme can change work inside a hospital and in the services receiving its patients.

The people involved

Chief pharmacists, clinical directors, medicines optimisation teams, operations, procurement and finance.

The dependencies

Specialist teams, general practice, community pharmacy, procurement, commissioners, digital and information-governance colleagues.

What to examine

Clinical applicability, staff capacity, implementation effort, continuity of care and full programme cost.

Explore the ecosystem

An illustrative set of programme relationships. The actual participants, authority, funding and permissions must be established for the defined setting. Explore every organisation perspective.

Start with the relevant national framework.

NHS England's biological medicines framework emphasises collaborative planning for best value (NHS England, n.d.). The local task is to establish the programme, population and operational requirements that apply in the actual setting. Avoid importing a national aspiration as a guaranteed local saving. A headline opportunity may depend on uptake, service capacity, product availability and commercial terms. The proposed brief would separate those dependencies, so pharmacy and specialist leaders can examine the conditions under which a programme makes operational and financial sense.

Compare the complete delivery requirement.

A pathway may involve education, prescribing-system work, ordering changes, administration arrangements and follow-up communication. Identify which costs are one-off and which recur. Show who provides the time and whether that capacity is available. An economic case should distinguish an acquisition-cost difference from the net result after implementation effort. It should also show which benefits accrue to which organisation. This gives a budget holder a usable decision rather than an attractive savings figure that cannot be delivered under current conditions.

A simple adoption case distinguishes the recurring acquisition difference from the cost of implementation and ongoing support. If the permitted inputs support it, reviewers can examine the period over which an observed recurring difference would cover one-off costs. Do not assume every eligible person changes at once or that uptake is linear. Show the sensitivity to timing and capacity, while leaving decisions about individual clinical suitability outside the organisational financial scenario.

Protect explanation and informed involvement.

A proposed organisational plan should identify who prepares and reviews information for people receiving treatment, who answers questions and how concerns return to the specialist team. It should not treat communication as an optional line at the end of mobilisation. Our first evaluation would examine whether these responsibilities are represented clearly in a planning brief. It would not decide that an individual should change treatment, generate unreviewed patient advice or present a population-level commercial case as a substitute for a professional conversation.

Use a bounded planning comparison.

PHARMORIS could be evaluated using approved programme documents, a defined implementation scenario and permitted aggregate resource assumptions. Compare its preparation support with the team's existing planning template. Pharmacy, specialist and finance reviewers would agree the critical dependencies before scoring the output. Inputs could initially be synthetic or historical, with no live prescribing changes. The task is to produce a source-linked plan that professionals can challenge; the study would not establish that a proposed switch programme has been implemented or that its benefits have occurred.

Measure quality before claiming value.

Candidate measures include essential actions identified, missing dependencies, clarity of ownership, assumptions requiring confirmation and total preparation plus correction time. A later operational evaluation could examine delivery milestones and observed implementation costs. Clinical outcomes and treatment experience would require suitable methods and specialist interpretation. The comparison should show where the proposed support succeeds and where human expertise remains the limiting factor. A useful development finding may be a narrower task that can be repeated reliably across programmes without overselling the scope of the technology.

Stop if the plan makes the decision for the person.

Stop if a draft implies automatic interchangeability at the individual level, overlooks a relevant local requirement or converts an uncertain price assumption into a guaranteed saving. Stop also if the effort needed to check the plan makes it less useful than the existing approach. The evaluation should allow the preferred scenario to lose. That discipline makes the proposition more investable: a repeatable business depends on solving real organisational work, not on presenting every implementation programme as an inevitable success.

Bring the next implementation question.

A specialist pharmacist, clinical service lead and finance or procurement owner can begin with the programme they are preparing and the decisions still unresolved. We can discuss a bounded preparation study, agreed sources and a fair comparator. The incentive is a clearer account of what delivery requires before the organisation commits capacity. PHARMORIS's role in that work remains a proposed development direction. Any pilot, data access or operational use would need its own defined scope and approval through the relevant local processes.

Sources and further reading

NHS England (n.d.) Best value biological medicines framework. Available at: https://www.england.nhs.uk/long-read/commissioning-framework-for-best-value-biological-medicines/ (Accessed: 14 October 2026).

Bring the question
your organisation
needs to move.

Tell us where the programme gets stuck, who is affected and what a worthwhile evaluation would help you decide.

Discuss a PHARMORIS evaluation

An initial conversation should describe the organisational question. Agree the purpose and information requirements before sharing records.

One programme. A whole system of people.

Original NEUVIOR motion explainer · 36 seconds · no audio. The film illustrates intended scope and questions for evaluation. Read the transcript.